Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 152

Sort by

Sort Order Select

Journal Articles

Prognostic significance of IKZF1 deletion subtypes in ph-negative BCP-ALL: Biallelic-null deletion predicts the worst survival in TP53-wild type patients

Seung-Hwan Lee, Daehun Kwag, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Heeje Kim, Chang-Ki Min, Seok-Goo Cho, Jae-Ho Yoon

Blood (2025) 146 (Supplement 1): 5149.

https://doi.org/10.1182/blood-2025-5149

Published: 2025

Journal Articles

Revisiting the role of second allogeneic HCT for post-transplant relapse in acute lymphoblastic leukemia: Comparative outcomes in the era of targeted therapies

Jaehyun Ahn, Daehun Kwag, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Heeje Kim, Chang-Ki Min, Seok-Goo Cho, Jae-Ho Yoon

Blood (2025) 146 (Supplement 1): 1548.

https://doi.org/10.1182/blood-2025-1548

Published: 2025

Journal Articles

Earlier detection of transplant-associated thrombotic microangiopathy using harmonization criteria: A real-world comparative evaluation with conventional criteria

Seonghan Lee, Byung-Sik Cho, Ka Young Kim, So Yeon Park, Kyoung Il Min, Hohyung Nam, Daehun Kwag, Jung Yeon Lee, Seonggyu Byeon, Gi June Min, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok-Goo Cho, Heeje Kim

Blood (2025) 146 (Supplement 1): 5999.

https://doi.org/10.1182/blood-2025-5999

Published: 2025

Journal Articles

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Blood (2025) 146 (Supplement 1): 1005.

https://doi.org/10.1182/blood-2025-1005

Published: 2025

Journal Articles

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Blood (2025) 146 (Supplement 1): 5514.

https://doi.org/10.1182/blood-2025-5514

Published: 2025

Journal Articles

Clinical outcomes and prognostic factors in AML patients undergoing second allogeneic hematopoietic stem cell transplantation

Hohyung Nam, Byung-Sik Cho, Hyunyee Rosa Cho, Ka Young Kim, Kyoung Il Min, So Yeon Park, Daehun Kwag, Seonggyu Byeon, Gi-June Min, Jung Yeon Lee, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok-Goo Cho, Heeje Kim

Blood (2025) 146 (Supplement 1): 7707.

https://doi.org/10.1182/blood-2025-7707

Published: 2025

Journal Articles

MRD-guided outcome analysis of ponatinib plus hyper-CVAD versus historical imatinib in ph-positive ALL: Impact of early response and dose-adjusted ponatinib

Kyoung Il Min, Daehun Kwag, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Heeje Kim, Chang-Ki Min, Seok-Goo Cho, Jae-Ho Yoon

Blood (2025) 146 (Supplement 1): 3327.

https://doi.org/10.1182/blood-2025-3327

Published: 2025

Journal Articles

Impact of initial FLT3-ITD mutated clone numbers on clinical outcomes in Acute Myeloid Leukemia

Daehun Kwag, Gi June Min, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok-Goo Cho, Heeje Kim

Blood (2025) 146 (Supplement 1): 1638.

https://doi.org/10.1182/blood-2025-1638

Published: 2025

Journal Articles

Clinical significance of apoe genotypes in older adults with Acute Myeloid Leukemia: Insights from a consecutively treated cohort

Daehun Kwag, Byung-Sik Cho, Gi June Min, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok-Goo Cho, Heeje Kim

Blood (2025) 146 (Supplement 1): 1636.

https://doi.org/10.1182/blood-2025-1636

Published: 2025

Journal Articles

Comparative efficacy of TBI-based vs. non-TBI reduced toxicity conditioning regimens in adult ALL undergoing allogeneic HCT in CR1: Improved outcomes with TBI-based RTC and ATG/ptcy combination

Kyung won Park, Jaehyun Ahn, Daehun Kwag, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Heeje Kim, Chang-Ki Min, Seok-Goo Cho, Jae-Ho Yoon

Blood (2025) 146 (Supplement 1): 4213.

https://doi.org/10.1182/blood-2025-4213

Published: 2025

Journal Articles

Evaluating the Impact of Absolute Lymphocyte Count on Outcomes in ATG Containing Haploidentical HSCT for Acute Myeloid Leukemia

Daehun Kwag, Jung Yeon Lee, Gi June Min, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Byoung-Sik Cho

Blood (2024) 144 (Supplement 1): 7327.

https://doi.org/10.1182/blood-2024-212406

Published: 2024

Journal Articles

Real-World Wutcome of Defibrotide for Treatment of Adult Patients Who Developed Severe Hepatic VOD/SOS after Allogeneic Hematopoietic Cell Transplantation

Jae-Ho Yoon, Daehun Kwag, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Seok Lee

Blood (2024) 144 (Supplement 1): 7326.

https://doi.org/10.1182/blood-2024-212062

Published: 2024

Journal Articles

Comparative Analysis of Treatment Outcomes in T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma: Implications for Allogeneic Hematopoietic Stem Cell Transplantation

Youngwoo Jeon, Tong-Yoon Kim, Kyoung Il Min, Gi-June Min, Ki-Seong Eom, Jong Hyuk Lee, Seok-Goo Cho, Jae-Ho Yoon

Blood (2024) 144 (Supplement 1): 7433.

https://doi.org/10.1182/blood-2024-205889

Published: 2024

Journal Articles

Real-World Experience of Blinatumomab for 8 Years Regarding Predictive Factors Including Lymphocyte Kinetics for Response and Survival Outcome in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

Seonghan Lee, Jae-Ho Yoon, Daehun Kwag, Gi-June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Seok Lee

Blood (2024) 144 (Supplement 1): 5903.

https://doi.org/10.1182/blood-2024-205680

Published: 2024

Journal Articles

Efficacy and Safety of Odronextamab in Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL): Data from the R/R MZL Cohort in the ELM-2 Study

Tae Min Kim, Seok-Goo Cho, Michal Taszner, Geoffrey Chong, Jingxian Cai, Amulya Uppala, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, John N. Allan

Blood (2024) 144 (Supplement 1): 862.

https://doi.org/10.1182/blood-2024-200190

Published: 2024

Journal Articles

Real-World Experience of Efficacy and Toxicity Issues of Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

Jae-Ho Yoon, Daehun Kwag, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Seok Lee

Blood (2024) 144 (Supplement 1): 5880.

https://doi.org/10.1182/blood-2024-212010

Published: 2024

Journal Articles

Single-Cell RNA Sequencing Elucidates Cellular Origin and Heterogeneity in Acute Myeloid Leukemia

Kyoung Il Min, Daehun Kwag, Jung Yeon Lee, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byoung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Hee-Je Kim

Blood (2024) 144 (Supplement 1): 6103.

https://doi.org/10.1182/blood-2024-204810

Published: 2024

Journal Articles

Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T-Naive and CAR-T-Exposed Patients

Blood (2024) 144 (Supplement 1): 868.

https://doi.org/10.1182/blood-2024-193681

Published: 2024

Journal Articles

Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 341.

https://doi.org/10.1182/blood-2024-193589

Published: 2024

Journal Articles

Trial in Progress: Odronextamab for the Treatment of Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Prior BTK Inhibitor Therapy - a Cohort of the ELM-2 Study

Seok-Goo Cho, Tae Min Kim, Michal Taszner, Tsai-Yun Chen, Aafia Choudhry, Melanie Ufkin, Amulya Uppala, Ayesha Sabir, Hesham Mohamed, Srikanth Ambati, Emmanuel Bachy

Blood (2024) 144 (Supplement 1): 6302.

https://doi.org/10.1182/blood-2024-200770

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic significance of IKZF1 deletion subtypes in ph-negative BCP-ALL: Biallelic-null deletion predicts the worst survival in TP53-wild type patients

Revisiting the role of second allogeneic HCT for post-transplant relapse in acute lymphoblastic leukemia: Comparative outcomes in the era of targeted therapies

Earlier detection of transplant-associated thrombotic microangiopathy using harmonization criteria: A real-world comparative evaluation with conventional criteria

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Clinical outcomes and prognostic factors in AML patients undergoing second allogeneic hematopoietic stem cell transplantation

MRD-guided outcome analysis of ponatinib plus hyper-CVAD versus historical imatinib in ph-positive ALL: Impact of early response and dose-adjusted ponatinib

Impact of initial FLT3-ITD mutated clone numbers on clinical outcomes in Acute Myeloid Leukemia

Clinical significance of apoe genotypes in older adults with Acute Myeloid Leukemia: Insights from a consecutively treated cohort

Comparative efficacy of TBI-based vs. non-TBI reduced toxicity conditioning regimens in adult ALL undergoing allogeneic HCT in CR1: Improved outcomes with TBI-based RTC and ATG/ptcy combination

Evaluating the Impact of Absolute Lymphocyte Count on Outcomes in ATG Containing Haploidentical HSCT for Acute Myeloid Leukemia

Real-World Wutcome of Defibrotide for Treatment of Adult Patients Who Developed Severe Hepatic VOD/SOS after Allogeneic Hematopoietic Cell Transplantation

Comparative Analysis of Treatment Outcomes in T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma: Implications for Allogeneic Hematopoietic Stem Cell Transplantation

Real-World Experience of Blinatumomab for 8 Years Regarding Predictive Factors Including Lymphocyte Kinetics for Response and Survival Outcome in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

Efficacy and Safety of Odronextamab in Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL): Data from the R/R MZL Cohort in the ELM-2 Study

Real-World Experience of Efficacy and Toxicity Issues of Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

Single-Cell RNA Sequencing Elucidates Cellular Origin and Heterogeneity in Acute Myeloid Leukemia

Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T-Naive and CAR-T-Exposed Patients

Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma

Trial in Progress: Odronextamab for the Treatment of Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Prior BTK Inhibitor Therapy - a Cohort of the ELM-2 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only